Quick Answer
RIGEL PHARMACEUTICALS INC reported Operating Income Loss of $125.47 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +418.6% in Operating Income Loss from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $26.98 million | Q3 2010: $50.36 million | Q1 2011: -$20.86 million | Q2 2011: -$21.56 million | Q3 2011: -$18.04 million | Q1 2012: -$23.31 million | Q2 2012: -$24.88 million | Q3 2012: -$25.57 million | Q1 2013: -$25.71 million | Q2 2013: -$22.89 million | Q3 2013: -$23.93 million | Q1 2014: -$22.39 million | Q2 2014: -$25.46 million | Q3 2014: -$21.04 million | Q1 2015: -$18.24 million | Q2 2015: -$13.97 million | Q3 2015: -$6.78 million | Q1 2016: -$17.57 million | Q2 2016: -$13.65 million | Q3 2016: -$22.74 million | Q1 2017: -$16.20 million | Q2 2017: -$19.34 million | Q3 2017: -$17.86 million | Q1 2018: -$24.73 million | Q2 2018: -$26.11 million | Q3 2018: -$24.37 million | Q1 2019: -$18.38 million | Q2 2019: -$21.34 million | Q3 2019: -$12.04 million | Q1 2020: $21.03 million | Q2 2020: -$17.39 million | Q3 2020: -$13.78 million | Q1 2021: $41.76 million | Q2 2021: -$13.05 million | Q3 2021: -$19.79 million | Q1 2022: -$26.26 million | Q2 2022: -$12.97 million | Q3 2022: -$18.40 million | Q1 2023: -$12.73 million | Q2 2023: -$5.27 million | Q3 2023: -$4.47 million | Q1 2024: -$6.97 million | Q2 2024: $447.0 thousand | Q3 2024: $14.06 million | Q1 2025: $12.77 million | Q2 2025: $61.10 million | Q3 2025: $28.42 million.
- Over the full 17 years of available data (2009 to 2025), RIGEL PHARMACEUTICALS INC's Operating Income Loss has grown by 212.0%.
- Historical annual values: Fiscal year 2025: $125.47 million | Fiscal year 2024: $24.19 million | Fiscal year 2023: -$20.49 million | Fiscal year 2022: -$55.55 million | Fiscal year 2021: -$12.50 million | Fiscal year 2020: -$28.97 million | Fiscal year 2019: -$69.09 million | Fiscal year 2018: -$72.68 million | Fiscal year 2017: -$79.62 million | Fiscal year 2016: -$69.74 million | Fiscal year 2015: -$51.74 million | Fiscal year 2014: -$91.25 million | Fiscal year 2013: -$89.47 million | Fiscal year 2012: -$99.38 million | Fiscal year 2011: -$86.37 million | Fiscal year 2010: $35.32 million | Fiscal year 2009: -$112.04 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: